The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed at a single center to predict outcomes for allogeneic transplant recipients who have comorbidities. The HCT-CI has not been widely validated in unselected transplant recipients. We evaluated whether the HCT-CI and other readily available pretransplant variables predicted NRM and OS at a Canadian transplant center. Using a prospective cohort design, we analyzed consecutive adult allogeneic HCT recipients. Of 187 patients, HCT-CI risk was low in 22 (12%), intermediate in 50 (27%), high in 104 (55%) and undetermined in 11 (6%). Two-year OS was 45% (95% CI: 24-64%), 55% (95% CI: 40-68%) and 42% (95% CI: 32-51%) in the low, intermediate and high-risk HCT-CI groups, respectively. Two-year NRM was 36% (95% CI: 17-56%), 26% (95% CI: 15-39%) and 30% (95% CI: 22-39%) in the low, intermediate and high-risk HCT-CI groups, respectively. In multivariate analysis, the HCT-CI failed to predict OS or NRM. However, KPS of o90% at HCT was a strong predictor of NRM. In conclusion, the HCT-CI was not associated with NRM or OS. In contrast, KPS was an independent indicator of survival. International multi-center studies are required before the HCT-CI is used in clinical practice.
Introduction
Comorbid illness is a recognized variable affecting survival in patients receiving treatment for both malignant and nonmalignant diseases. The impact of comorbidity on posttherapeutic outcome can be quantified by the Charlson Comorbidity Index (CCI), which assigns weighted scores to 19 statistically significant comorbid conditions. 1 The CCI has been widely used as a prognostic indicator and has been validated in multiple medical settings. [2] [3] [4] [5] [6] [7] Despite its broad application, investigators have found that prognostic power can be increased when the scored indices are tailored to the primary disease and its accompanying treatment modality. [8] [9] [10] Sorror et al. 10 modified the CCI to improve prognostication for patients with hematological malignancies receiving allogeneic hematopoietic cell transplantation (HCT). This devised hematopoietic cell transplantation-specific comorbidity index (HCT-CI) expands on the original CCI by including newly identified comorbidities and the refinement of comorbidity definitions. The HCT-CI was found to have greater sensitivity and improved survival prediction over the CCI, a finding that was confirmed at a separate US site. 11 Since its creation in 2005, the HCT-CI has been validated as a prognostic indicator for US-based patients requiring allogeneic HCT for both unselected hematologic diseases 12 and for acute myeloid leukemia in first remission. 13 Investigators from Japan 14 and the United Kingdom 15 have examined the prognostic power of the HCT-CI in patients undergoing allogeneic HCT with reduced-intensity conditioning regimens. Similar studies have not, to our knowledge, been performed in either ablative or reducedintensity conditioning HCT at a Canadian center. Independent of comorbidity, functional status has been demonstrated to have prognostic power for non-relapse mortality (NRM) and overall survival (OS) of oncology patients, including those undergoing HCT. [16] [17] [18] [19] [20] Functional status is commonly assessed using subjective measurements such as the Karnofsky Performance Status (KPS) and the Eastern Cooperative Oncology Group (ECOG) scale. Artz et al. proposed that functional status and comorbidity are sufficiently important that both should be considered in a composite risk score. 16 Sorror et al. also supported the inclusion of the KPS score, in addition to the HCT-CI score, in pre-transplant assessment of patients undergoing HCT. 21 The primary objective of this study was to evaluate whether the HCT-CI predicts NRM and OS in allogeneic transplant recipients at a Canadian center. As the HCT-CI does not incorporate the functional status, a potentially important prognosticator, our secondary objective was to evaluate whether KPS predicts NRM and OS.
Patients and methods
We used a prospective cohort design. The Manitoba Blood and Marrow Transplant Program collects relevant demographic and clinical data for all patients undergoing HCT in Manitoba, a province of approximately 1.2 million. Consecutive adult recipients of allogeneic HCT between 1 January 1990 and 31 December 2005 were included in the study.
Patients received ablative TBI-based regimens for all unrelated donor transplants or lymphoid malignancies. Chemotherapy-based regimens were used for all other patients. In general, eligibility criteria for transplantation included a KPS of X60% (ECOG 0-2) and the presence of adequate organ function as deemed by the treating BMT physician. As of October 2005, non-myeloablative regimens were utilized for patients with advanced age (X55 years). Hematopoietic cell source was from either related or unrelated donors. Post-grafting immune suppression comprised CYA or tacrolimus, in addition to short-course MTX. Primary treatment of acute and chronic GVHD consisted of systemic corticosteroids, and continuation or reinstitution of calcineurin inhibitors.
Early PCR-based detection of cytomegalovirus and preemptive gangciclovir therapy were used for all patients, as were standard prophylaxis against Candida infections (fluconazole), bacterial infections (ciprofloxacin), Pneumocystis jirovecii infection (trimethoprim-sulfamethoxazole or dapsone), and herpes simplex virus in serologically positive patients (acyclovir).
Pertinent information was extracted from The Manitoba Blood and Marrow Transplant Program database by a qualified health information technologist. Supplementary data were obtained from electronic and paper charts by a medical student investigator. This process was completed under the direct supervision of a hematologist/oncologist with expertise in blood and marrow transplantation. Patient outcomes, including dates of progression/relapse, death and last contact were identified. The specific causes of death and, where available, subsequent autopsy reports were collected. Follow-up was terminated on 31 December 2005. Patients were censored at end of follow-up or death.
Comorbidities were collected according to their HCT-CI classification. 10 Specific comorbidities included: arrhythmia, heart valve disease, cardiac, inflammatory bowel disease, diabetes, cerebrovascular disease, psychiatric disturbance, chronic hepatitis, obesity, infection, rheumatologic disease, peptic ulcer, renal failure, decreased pulmonary function and prior solid tumor. Each patient was assigned a comorbidity score and was stratified into low (0), intermediate (1-2) and high-risk (X3) groups based on their total score. Pre-transplant comorbidities requiring quantitative measurement included obesity, cardiac, hepatic, renal and pulmonary comorbidities. The aforementioned diagnostic data were obtained within a 1-month window before HCT as part of routine pre-transplant work-up. Patients whose diagnostic data were older than 1 month were excluded from the study. Likewise, patients with pulmonary function tests that were not corrected for hemoglobin were excluded from the study. All other active diagnoses, as defined by the HCT-CI, were included in the study even if they fell outside this 1-month window.
Disease risk was categorized as either low (acute leukemia in first remission; CML in first chronic phase; MDS-refractory anemia; non-malignant hematological disease) or high (all other diagnoses). 10 Patients were classified into older (X40) and younger (o40) age groups, based on the cohort's median age of 39 years.
KPS score was measured and documented by the treating BMT physician at the time of hospital admission. KPS scores were categorized as low (o90%) or high (X90%). A KPS score of X90% was used as the reference point because it corresponds to an ECOG score of 0, facilitating the translation from the ECOG to the Karnofsky system. In addition, the use of a lower cutoff point for KPS was impractical in that the great majority of HCT recipients have KPS scores of X80%.
Our study period pre-dated the paper by Sorror et al.
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by 6 years. This may be significant because treatment protocols and supportive care not only undergo modern refinement but may also impact upon outcome and survival. To account for these potential influences in multivariate analysis, the era of transplant was separated into two groups: those receiving HCT between 1991 and 1998, and those receiving HCT between 1999 and 2005. We examined the relationship between KPS and HCT-CI using the Spearman's rank correlation. The Kaplan-Meier method was used for estimating time to event. Comparisons between survival estimates across variable categories were performed using the Cox proportional hazards model. OS and NRM were defined as the time from day 0 of the transplant to death from any cause and death from nonrelapse causes, respectively.
Multivariate analysis for independent factors predicting NRM and OS included the following five categorical variables: HCT-CI risk (0, 1-2, X3), age (o40, X40 years), era of HCT (early, late), disease risk (high, low) and KPS at HCT (o90%, X90%). Data management and analyses were performed using SAS 9.1.3.
Permission to perform this study was obtained from the University of Manitoba's Health Research Ethics Board.
Results
A total of 187 patients were identified. The characteristics of these patients are displayed in Table 1 . Over half of the patients were male (60%) and the median age at transplant was 39 years. High-risk disease was present in 61% of patients. Preparative regimens were myeloablative in the majority of patients (95%). In all 74% of patients received grafts from related donors. Stem cell source was marrow in 72% of patients. HCT-CI risk category was low in 22 (12%), intermediate in 50 (27%), high in 105 (56%) and undetermined in 11 (6%) because of either missing or untimely quantitative comorbidity measurements. Fiftytwo percent had KPS scores of X90%. KPS scores were not documented for 22 patients (12%).
The prevalence of specific comorbidities is shown in Table 2 , with comparison to the prevalence rates reported by Sorror et al. 10 The current study population had relatively high instances of both mild (39 vs 16%) and moderate/severe (14 vs 4%) hepatic disease, moderate (37 vs 24%) and severe (29 vs 9%) pulmonary disease and obesity (10 vs 2%) in comparison to the Seattle study population. 10 Two-year cumulative NRM was 36% (95% CI: 17-56%), 26% (95% CI: 15-39%), and 30% (95% CI: 22-39%) in the low, intermediate and high-risk HCT-CI groups respectively (Figure 1) . Two-year OS was 45% (95% CI: 24-64%) in the low-risk group, 55% (95% CI: 40-68%) in the intermediate-risk group and 42% (95% CI: 32-51%) in the high-risk HCT-CI groups. In univariate analysis, the HCT-CI was a poor predictor of NRM and Estimates of OS and NRM stratified by KPS are shown in Figure 2 . There were statistically significant advantages in both OS and NRM for patients with a KPS of X90%. There was no correlation between KPS and HCT-CI using Spearman's rank correlation (r ¼ À0.13, P-value: 0.10).
Multivariate analysis was restricted to 155 patients, owing to missing KPS data for 22 patients (Table 3) . HCT-CI risk was not a significant predictor of NRM and OS. Furthermore, there did not appear to be a gradient to support increasing risk of overall or non-relapse mortality with increasing HCT-CI score. Similarly, age at HCT was also found to have no significant impact on NRM or OS.
Of the variables considered in the multivariate analysis, only KPS at time of transplant and disease risk were found to be statistically significant. NRM was lower (hazard ratio (HR): 0.54, 95% CI 0.30-0.95) in patients with KPS X90%, whereas OS was superior (HR: 0.65, 95% 0.42-1.01) in those with KPS X90%. High-risk disease was found to correlate strongly with decreased OS (HR: 2.21, 95% CI 1.37-3.57) but had little effect on NRM (HR: 1.53, 95% 0.84-2.79). NRM tended to be lower for those receiving HCT after 1998 (HR: 0.61, 95% CI 0.33-1.11) but OS was not affected.
Discussion
The potential for pre-transplant comorbidities to negatively impact on outcomes of allogeneic HCT has been suggested in previous reports. 10, 22 The HCT-CI was created to identify the cumulative comorbidity risk for patients receiving allogeneic HCT. Before the present study, the HCT-CI had not been validated widely, and had not been examined at all in patients at a Canadian institution. Our primary objective was to determine the validity of the HCT-CI as a predictive tool of NRM in patients receiving an allogeneic transplant at a Canadian transplant center. Our secondary objective was to evaluate whether KPS, a potentially important prognosticator, predicts NRM and OS. When applied to our patient population the HCT-CI was not found to be predictive of either NRM or OS. Results from both unadjusted and adjusted analyses demonstrated no survival advantage for patients with low-risk HCT-CI scores. Further exploratory analysis (not shown in this paper) using a modified 2-group scoring system of low-risk (0-3) and high-risk (44) HCT-CI groups, which in a previous report 12 was used to successfully stratify patients within a small sample size, still failed to show even a trend that supported the validity of the HCT-CI as a prognostic indicator.
Although HCT-CI was not found to have prognostic value in our study, KPS scores before transplant were found to have a prognostic value. KPS, when stratified into scores of less than 90% and greater than 90% at BMT, had a significant predictive value for NRM and OS. This finding is consistent with previously published data. 16 According to our data, this simple and inexpensive measurement is a powerful predictor of post-HCT outcomes.
In addition to HCT-CI and KPS, three other variables including disease risk, era of transplant and age were analyzed to determine their independent influence on NRM and OS, as well as their potential influence on the HCT-CI. Disease risk and era of transplant were found to be significant indicators of post-HCT outcome. High-risk disease was strongly predictive of OS, and our study population had a comparatively high prevalence of patients with high-risk disease compared with that of Sorror et al. 10 This difference in prevalence could potentially affect the predictive power of the HCT-CI if patients with low-risk (0) HCT-CI scores had a proportionately higher incidence of high-risk disease than patients with intermediate-risk (1) (2) and high-risk (X3) HCT-CI scores.
Era of HCT was found to be predictive of NRM. This variable was considered in a multivariate analysis because our study period dated back to 1991, 6 years earlier than the study conducted by Sorror et al.
10
Transplants conducted after 1998 corresponded, with lower NRM (HR: 0.61, 95% CI 0.33-1.11). This is possibly a result of refinements in supportive care strategies. As such, patients in the Seattle study may have received more uniform supportive care.
One variable that was not included in the study, but has been shown to impact on outcome, is socioeconomic status. [23] [24] [25] This variable may be pertinent to our study because our patient population, unlike that of the Sorror et al. study, 10 is based on a universal health care system, which minimizes referral bias. According to generalized population studies, significant disparity in access to health care between Canada and the United States is present. 26 This finding was substantiated by the United States General Accounting Office in their 1994 report of access to and appropriate use of HCT. 27 Canada was identified as having equivalent, if not superior availability and appropriate utilization of HCT. As such, the population profile of HCT recipients in Canada, including socioeconomic status, may not be equivalent to that found in the United States. We suggest that international discrepancies in access and utilization of HCT may limit the universality of the HCT-CI.
Apart from the identified differences in access to health services between our study population and the Seattlebased population of Sorror et al., 10 several patient characteristics were also found to differ between the two studies. The youngest patient included in our study was no less than 17 years old, whereas the Seattle study included at least one 10-month-old patient. The proportion of related donors was higher in our study (74 vs 58%) and the principle source of hematopoietic cells was marrow as opposed to peripheral blood.
One of the more striking differences between the two study groups was the high incidence of comorbidities within our Canadian population. Our study population had relatively high instances of hepatic disease, pulmonary disease and obesity when compared with the Seattle study population. 10 These discrepancies could be attributed to more permissive eligibility criteria for HCT at our center. Despite having a population burdened with greater comorbidity, patients with high-risk HCT-CI scores had lower NRM in our study (30 vs 41%).
The high number of patients with moderate or severe pulmonary disease in our cohort deserves further mention. We were fortunate to be able to assign patients a level of pulmonary impairment using objective measurements from pulmonary function testing, in contrast to a more subjective score based on symptoms. These detailed tests were performed and reported at a single tertiary care respiratory unit. Gas transfer was corrected for hemoglobin. We thus feel that our assessment of pre-HCT pulmonary function was accurate and free of information bias.
Furthermore, we did not specify a minimum level of pre-HCT pulmonary function that would either require a switch from a TBI-based to a chemotherapy-based regimen. The BMT program chose to adhere to pre-specified conditioning regimens depending on disease and donor type: TBI was used for patients with lymphoid malignancies and for recipients of unrelated donor transplants. We did not make any routine modifications in terms of dosage or drugs used for patients with pulmonary impairment. Specifically, the technique of delivering TBI remained constant. Thus, tailoring of the conditioning regimen for patients with pulmonary disease was likely to be rare, and is unlikely to represent a significant source of selection bias.
The principal limitation to our study was small sample size (187 patients). This sample size was further reduced (155 patients) for multivariate analysis of KPS scores. Notwithstanding, our sample size is still larger than several other American 28 and International studies, 14,15 whose small populations did support the validity of the HCT-CI in predicting NRM and/or OS. Furthermore, we are confident that our stringent data collection has minimized information bias as a significant flaw in our analysis.
In contrast to other international studies, 14, 15 our study of a Canadian population failed to show even a trend that supports the predictive power of the HCT-CI for NRM or OS. To determine the validity of the HCT-CI within a Canadian population, a multi-centered collaboration is necessary to produce an adequately powered validation study.
In conclusion, the HCT-CI was not found to be predictive of either NRM or OS in patients receiving HCT at a Canadian center. Further investigation of the HCT-CI in the context of prospective data collection with a large sample size in a multi-center setting is ideal. In addition, a systematic review and meta-analysis of the utility of the HCT-CI may be helpful. In contrast, the KPS was found to be a useful tool in predicting NRM and OS. This finding supports the continued inclusion of the KPS both in assisting treatment decisions and in future research that evaluates transplant-related outcomes.
